GSK drops out of Vertex pact for HIV therapy

GlaxoSmithKline has dropped out of its pact with Vertex to develop the experimental HIV drug brecanavir, saying it will be too difficult to develop the proper formulation of the drug. The therapy is in mid-stage trials. Vertex notes that the two companies have been collaborating since 1993 and have developed two approved therapies for HIV.

- here's the AP report on GSK's move

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.